Supplementary Methods, Supplementary Figures 1-6 from Targeting RET Kinase in Neuroendocrine Prostate Cancer

Authors:

Abstract
Supplemental Figure 1. RET expression is higher in prostate cancer lines that have lost androgen receptor signaling Supplemental Figure 2. RET gene expression is higher in patient samples with pure/mixed small cell phenotype or primary NEPC and correlates with other neuroendocrine markers. Supplemental Figure 3. Knockdown of RET kinase in PC3 cells shows a modest reduction in cellular proliferation. Supplemental Figure 4. Prostate cancer cell lines show variable sensitivity to RET inhibitor treatment. Supplemental Figure 5. Organoids derived from PTEN-/- and Rb-/- prostate cells model multiple aspects of NEPC including resistance to enzalutamide treatment. Supplemental Figure 6. A higher dose replicate of AD80 treatment of NCI-H660 xenograft tumors shows a similar effect of restricting tumor growth.